SPS
ADCT icon

Susquehanna Portfolio Strategies’s ADC Therapeutics ADCT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Hold
64,523
– – ﹤0.01% 880
2025
Q4 		$228K Hold
64,523
– – ﹤0.01% 928
2025
Q3 		$258K Buy
64,523
+21,097
+49% +$66.5K ﹤0.01% 944
2025
Q2 		$116K Buy
+43,426
New +$91.3K ﹤0.01% 815

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna Portfolio Strategies's ADCT Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 64,523 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

Susquehanna Portfolio Strategies first reported a position in ADCT in Q2 2025 and has held it in 4 quarters since. The position peaked at $258K in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Susquehanna Portfolio Strategies held 64,523 shares of ADC Therapeutics worth $242K as of Q1 2026.
  • Susquehanna Portfolio Strategies left its ADC Therapeutics share count unchanged in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #880 holding.
  • Susquehanna Portfolio Strategies first reported a position in ADC Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's ADC Therapeutics position peaked at $258K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.